Transmyocardial laser revascularization: Clinical experience with twelve-month follow-up

We are investigating a new technique for myocardial revascularization in which an 800 W carbon dioxide laser is used to drill 1 mm diameter channels into a beating heart after left thoracotomy. Clotting occludes the channels on the subepicardium, and in the Long-term setting, blood from the left ventricular cavity flows through these channels to perfuse the ischemic subendocardium. To test the efficacy of this technique in a preliminary clinical trial, we used it as sole therapy for 21 consecutive patients, All patients had hibernating myocardium, reduced coronary flow reserve, or both, had distal diffuse coronary artery disease, and had angina refractory to normal therapy, Eight patients were excluded from follow-up because of death (n = 5), rerevascularization (n = 2), or diaphragmatic paralysis resulting in postoperative respiratory incapacity (n = 1), In the remaining 13 patients available for follow-up, the mean angina class (Canadian Cardiovascular Society) was 3.7 +/- 0.4 before operation and 1.8 +/- 0.612 months after operation (p < 0.01), Mean resting left ventricular ejection fraction was 38% +/- 10% before operation and 50% +/- 8% at 12-month follow-up, At 12 months, resting mean subendocardial/subepicardial perfusion ratio had increased by 20% +/- 9% in septal regions treated by laser but decreased by 2% +/- 5% in untreated regions (n = Il,p <.001), These results suggest that revascularization by this laser technique positively affects subregional myocardial perfusion and may result in clinical benefits for patients with reversible myocardial ischemia, Studies to date have not demonstrated significant changes in global and regional ventricular contractile function.